Compare UVSP & CRVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | UVSP | CRVS |
|---|---|---|
| Founded | 1876 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 1.1B |
| IPO Year | 1994 | 2016 |
| Metric | UVSP | CRVS |
|---|---|---|
| Price | $43.14 | $15.10 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 3 | 6 |
| Target Price | ★ $36.67 | $30.17 |
| AVG Volume (30 Days) | 260.9K | ★ 815.8K |
| Earning Date | 04-22-2026 | 05-07-2026 |
| Dividend Yield | ★ 2.44% | N/A |
| EPS Growth | 21.32 | ★ 48.04 |
| EPS | ★ 1.78 | N/A |
| Revenue | ★ $328,056,000.00 | N/A |
| Revenue This Year | $11.65 | N/A |
| Revenue Next Year | $4.77 | N/A |
| P/E Ratio | $24.12 | ★ N/A |
| Revenue Growth | ★ 9.64 | N/A |
| 52 Week Low | $28.04 | $4.92 |
| 52 Week High | $45.46 | $26.95 |
| Indicator | UVSP | CRVS |
|---|---|---|
| Relative Strength Index (RSI) | 46.76 | 63.50 |
| Support Level | $42.55 | $14.24 |
| Resistance Level | $43.26 | $16.66 |
| Average True Range (ATR) | 0.75 | 0.70 |
| MACD | -0.26 | 0.16 |
| Stochastic Oscillator | 33.23 | 93.45 |
Univest Financial Corp is engaged in domestic banking services for individuals, businesses, municipalities and non-profit organizations. The bank has three operating segments; Banking segment provides financial services including a full range of banking services such as deposit taking, loan origination, and servicing, mortgage banking, other general banking services, and equipment lease financing, Wealth Management segment offers investment advisory, financial planning, trust and brokerage services, and The Insurance segment includes a full-service insurance brokerage agency offering commercial property and casualty insurance, employee benefits solutions, personal insurance lines and human resources consulting. It generates majority of its revenue from the banking segment.
Corvus Pharmaceuticals Inc is a clinical stage biopharmaceutical company developing product candidates that precisely target proteins that are critical to immune cell maturation and function. It believes its proprietary product candidates have broad potential to address immune mediated diseases, inflammatory diseases and cancers. Its product candidate, soquelitinib, is designed to bind specifically to a protein, interleukin 2 inducible T cell kinase (ITK), involved in T cell activation, T cell receptor signaling and T cell differentiation and function. The company operates in one primary business activity and operate as one reportable segment.